CVS Caremark’s foray into cost-effectiveness analysis raises questions about the future of prescription medicines in America

Written By: Americans spend more on prescription drugs than anyone else in the world. In a move to address this, CVS Caremark announced in August that it would allow self-funded insurers to exclude from their plan any drug launched at… Continue Reading

Paying for Specialty Pharmaceuticals: The Case of Injectable Oncology Drugs

According to the American Cancer Society, the financial costs of cancer are high for both the person with cancer and for society as a whole. The National Institutes of Health (NIH) estimated the 2009 overall annual costs of cancer in… Continue Reading

Integration of Novel Diagnostics into Clinical Practice

Similar to drug and device markets, a critical part of the success of novel diagnostics is educating providers on clinical and therapeutic utility.  However, unlike pharmaceutical drugs, the ordering of a diagnostic test does not necessarily imply a change in… Continue Reading

21st Century Cures and Off-Label Promotion Benefit HEOR and Drug Safety

As my writing for the AdverseEvents Blog can attest, I’m in favor of data transparency. In my view, no organization should have monopolistic control over important information that limits the ability for healthcare decision makers to perform unbiased, objective comparative… Continue Reading